President Donald Trump is set to pick oncologist Stephen Hahn, currently chief medical executive at MD Anderson Cancer Center in Houston, as the next FDA commissioner, forgoing current leader Ned Sharpless.
This is according to The Wall Street Journal, citing sources “familiar with the matter.”
The sources told the WSJ the pick is expected to be confirmed next week, in time for the end of Sharpless’ acting tenure, which is up Nov. 1. The Senate would need to confirm a new commissioner.
Sharpless took over on a temporary basis after media and biopharma favorite Scott Gottlieb unexpectedly left in the spring, later to take on a series of healthcare company roles.
Sharpless, formerly director of the National Cancer Institute, is still seen as a front-runner, but Hahn, formerly chairman of radiation oncology at the University of Pennsylvania School of Medicine, has been edging into the race in recent weeks, according to reports.
The FDA has been undergoing something of a cultural shift in recent years, with a focus on speedy reviews but arguably at the expensive of a slower, more considered approach to drug approvals.
Some greenlights, such as for Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) therapy three years ago, saw internal and external wrangling at the regulator about whether the bar was being lowered. There are also whispers as to how political the FDA’s rejection of Sarepta’s second attempted DMD approval was, and as a backlash to its first.
With Trump being elected in 2016 and his mandate of slashing regulation in general to cut costs and boost efficacy, concerns deepened that his pick(s) may lower that bar further.
A big test of this is on the horizon: namely, with Biogen’s once failed and canned Alzheimer’s disease drug aducanumab, now resurrected in time for Halloween and set to spook more than a few FDA insiders.
Biogen, working some data magic/dredging operation, found that their drug may actually work in some Alzheimer’s patients, though skepticism is sky-high from some analysts and bio-Twitterati (though investors, not so much).
Biogen had it said spoken with the FDA, which appeared happy for it to attempt to file the drug. Anything could happen: a refuse to file notice, a demand for another phase 3 trial, a hostile AdComm, even a flat-out no. Whatever the decision and path, this will be a litmus test for any commissioner as well as the FDA itself.
By Ben Adams
Source: Fierce Biotech
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
